These are publications from work undertaken by Frontier Science (Scotland).

D Cameron;  M Piccart-Gebhart; RD Gelber; M Procter; A Goldhirsch; E. de Azambuja; G Castro Jr; M Untch; I Smith; L Gianni; J Baselga; N Al-Sakaff; S Laver; E McFadden; B Leyland-Jones; R Bell; M Dowsett; C Jackisch;  March 25, 2017

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial,  Volume 389, Issue 10075, pp. 1195-1205, doi:10.1016/S0140-6736(16)32616-2

S Di Cosimo;  C Campbell; H A Hazim; G Curigliano; R Crescenzo; L de la Pena; M Piccart-Gebhart; H. Eidtmann; J Baselga; E. de Azambuja;  2016

Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)

Cancer Research,  Volume 76, Issue 4, doi:10.1158/1538-7445.SABCS15-P6-01-04

E McFadden;  S Bashir; S Canham; J Darbyshire; P Davidson; S Day; S Emery; J Pater; S Rudkin; M Stead; J Brown;  2015

The impact of registration of clinical trials units: the UK experience

Clinical Trials,  Volume 12, Issue 2, Pages 166-173, doi:10.1177/1740774514561242

O Metzger-Filho;  E. de Azambuja; M Procter; M Krieguer; I Smith; J Baselga; D Cameron; M Untch; C Jackisch; R Bell; L Gianni; A Goldhirsch; M. Piccart; RD Gelber; HERA Study Team;  2016

Trastuzumab Re-Treatment Following Adjuvant Trastuzumab and the Importance of Distant Disease-Free Interval: the HERA Trial Experience

Breast Cancer Research and Treatment,  Volume 155, Issue 1, Pages 127-132,doi: 10.1007%2Fs10549-015-3656-0

A Goldhirsch;  RD Gelber; M Piccart-Gebhart; E. de Azambuja; M Procter; T M Suter; C Jackisch; H A Weber; D Heinzmann; L D Lago; E McFadden; M Dowsett; M Untch; L Gianni; R Bell; A Vindevoghel; M Andersson; C Köhne; D Cameron;  2013

2 Years Versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial

The Lancet,  Volume 382, Issue 9897, Pages 1021-1028, doi: 10.1016/S0140-6736(13)61094-6

O Metzger-Filho;  M Procter; E. de Azambuja; B Leyland-Jones; RD Gelber; M Dowsett; S Loi; K S Saini; D Cameron; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; R Bell; C Sotiriou; G Viale; M Piccart-Gebhart;  2013

Magnitude of Trastuzumab benefit in patients with HER2 positive, invasive lobular breast carcinoma: results from the HERA trial

Journal of Clinical Oncology,  Volume 31, Issue 16, Pages 1954-1960, doi: 10.1200/JCO.2012.46.2440

L Gianni;  U Dafni; RD Gelber; E. de Azambuja; S Muehlbauer; A Goldhirsch; M Untch; I Smith; J Baselga; C Jackisch; D Cameron; M Mano; J Luiz Pedrini; A Veronesi; C Mendiola; A Pluzanska; V Semiglazov; E Vrdoljak; M J Eckart; Z Shen; G Skiadopoulos; M Procter; KI Pritchard; R Bell;  2011

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow up of randomized controlled trail

The Lancet,  Volume 12, Issue 3, Pages 236-244, doi: 10.1016/S1470-2045(11)70033-X

M Procter;  T M Suter; E. de Azambuja; U Dafni; V Van Dooren; S Muehlbauer; M Angel Climent; E Rechberger; W Tsang-Wu Liu; M Toi; R C Coombes; D Dodwell; O Pagani; J Madrid; M Hall; S Chen; C Focan; M Muscholl; D J van Veldhuisen; M Piccart-Gebhart;  2010

Longer term assessment of trastuzumab for 1 year after adjuvant chemotherapy

Journal of Clinical Oncology,  Volume 28, Issue 21, Pages 3422-3428, doi: 10.1200/JCO.2009.26.0463

M Dowsett;  M Procter; M McCaskill-Stevens; M E de Azambuja; U Dafni;  2009

Disease free survival according to the degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year trastuzumab: the HERA trial

Journal of Clinical Oncology,  Volume 27, Issue 18, Pages 2962-2969, doi: 10.1200/JCO.2008.19.7939

M Untch;  RD Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; B Leyland-Jones; E. de Azambuja; R Khasanov; F Feng-yi; C Constantin; J Mayordomo; C H Su; S Y Yu; E Senkus-Konefka; A Lluch; P Wermuth; C Price;  2008

Estimating the Magnitude of Trastuzumab effects within patient subgroups in the HERA trial

Annals of Oncology,  Volume 19, Issue 6, Pages 1090-1096, doi: 10.1093/annonc/mdn005